Last reviewed · How we verify

NCT05337059: PULMOESO

Feasabilty and Physiological Effects of a Ventilation Strategy Combining PEEP and Tidal Volume Titration According to Inspiratory and Expiratory Transpulmonary Pressures in ARDS Patients.

Completed NA Last updated 14 April 2026
What this trial tests

NA trial testing PEEP and Tidal Volume Titration in ARDS, Human in 9 participants. Completed in 1 April 2026.

Timeline
30 March 2022
Primary endpoint
4 March 2026
1 April 2026

Quick facts

Lead sponsorUniversity Hospital, Angers
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment9
Start date30 March 2022
Primary completion4 March 2026
Estimated completion1 April 2026
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Angers

Who can join

18 and older, any sex, with ARDS, Human. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Expiratory or inspiratory transpulmonary pressures have been proposed to optimize ventilator settings in patients with ARDS. The aim of this study is to assess the feasibility and the physiological effects of a new method based on both expiratory and inspiratory transpulmonary pressures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for ARDS, Human

Currently open trials in the same condition.

Other University Hospital, Angers trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05337059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing